All News

Article

Telemedicine Enriched Care Model for Autoinflammatory Diseases

Bella Mehta, MBBS, MS Nov 09, 2021

Traditionally telemedicine is thought to be a technology where a patient directly talks to a provider or a specialist; however, another concept of having a patient with a local primary care who in turn accesses specialists via video conferencing, is gaining some momentum.

Work participation in patients with axSPA Patients w/ axSpA often have increased absence from work as well as reduced productivity at work, which can lead to wider economic & social burden. Dr. Dey (@DrMiniDey) discusses abstracts from #ACR21. https://t.co/eAMLPR2zoT https://t.co/NuIajGa7gx

https://bit.ly/3BTBqXG

Methotrexate did not improve Ustekinumab efficacy in tx of PsA ⭐️Addition of MTX did not improve dactylitis, enthesitis, skin, QoL or function #ACR21 #ACRBest @RheumNow Abs#L12 https://t.co/6dxWPNskou https://t.co/BnzH8PfaMV

https://bit.ly/3wvtoDl

Very interesting talk Abst L16 Singh & colleagues found that patients with rheumatic diseases are at increased risk for breakthrough infxn - Recent drug exposure and certain medication type can influence outcomes - Findings support need for 3rd dose in RD pts #ACR21 @RheumNow https://t.co/vU6ZNIEWbc

Prevalent drug utilization unrelated to enthesitis in PsA. Pts on cDMARDs had higher physician globals vs those treated w/TNFi & IL-17i. In aggregate, no pattern of dz activity scores correlation w/drugs. Abs 1782 #ACR21 #RheumNow @RheumNow @doctorRBC https://t.co/x57BkBjpjo https://t.co/QmdXqOxLki

Disease Activity in Psoriatic Arthritis Patients with Enthesitis Across Differe…

Phase 2 trial of tildrakizumab (IL-23i) for the treatment of PsA showed lower efficacy in pts with metabolic syndrome compared to those without #ACR21 @RheumNow Abs#1819 https://t.co/GYHbiH9NSW https://t.co/YGcZcITjzj

https://bit.ly/3mX3Lb4

USA EMR (N3C) Data on 577,335 Rheum Pts w/18,164 #COVID19 breakthrough infx (BTI) 👉91% vax'd 👉3.1% w/BTI 👉86% were vax'd May 2021 or earlier 👉More BTI w/Pfizer 👉BTI higher in inflamm myositis, RA 👉Drugs assc w/BTI: biologics, mult DMARDs #ACR21 @rheumnow Abst#L16 #ACRbest https://t.co/Eu77vAAk3N

Patients with acute calcium pyrophosphate arthritis at ⬆️risk of cardiovascular events. Abstr#1898 #ACR21 @RheumNow https://t.co/IOFYJnutHM

Why would higher active dose of #methotrexate with sc admin & more metabolites polyglutamates which can give side effects have LESS AEs? Never understood it! #ACR21 abst#1695 @RheumNow https://t.co/qrEKofX1cl

Richard Conway on Twitter: "Dr Hebing on s/c vs oral methotrexate. erythro…

Abst1810 #acr21 @RheumNow survey of pt preferred meds for PsA points out ⬆️ interest in IL17 & PDE4 since 2018 guideline update: anti-IL17 compared to 2018 or earlier (30% vs 3.5% p< 0.001);anti-PDE4 (40% vs 11.5% p< 0.012). Meds SEs& prevention of joint damage important for pts

#ACR21 L16 - Breakthrough #COVID19 in rheum pts ⭐️Breakthrough ifn ~4%, compared to 3% wo rheum disease. Statistically signif ⬆️ risk in RA, gout, polymyositis, vasculitis, multiple rheum disease ⭐️bDMARD, multiple AIRD risks @Rheumnow https://t.co/cuM9LcEr4u https://t.co/Los2n7BoIn

https://bit.ly/3mUsMUp

After 2018 ACR Guidelines, significant increase in IL-17i and PDE4i use in PsA pts ⭐️TNFi most common tx ⭐️28% pts not on any tx⭐️ #ACR21 @RheumNow Abs#1810 https://t.co/7Rmirfm3nK https://t.co/0Ui9pq5uyo

https://bit.ly/3BSU029

RHEKISS registry: SpA pts on bDMARDs at conception are NOT at inc. risk for adverse pregnancy outcomes. Discontinuation of bDMARDs after conception is assoc'd w/ inc. dz activity during/after pregnancy & flare risk. Abs 1730 #ACR21 #RheumNow @RheumNow https://t.co/b2wI9GZios https://t.co/wsuvv3hF0v

Disease Activity and Outcome in Pregnancies of Patients with SpA - Data from th…

The plague protection genetically can lead to Pyrin induced inflammasome activation. Theory of more FMF in Mediterranean / Turkey. So high protection gene in population Dan Kastner - a genetic detective 9T119 #ACR21 #ACRBest @RheumNow https://t.co/qzdc12fT0j

In Phase 2 trial of Tildrakizumab in active PsA efficacy tended to be lower among patients with comorbid MetS, with improvements from baseline across efficacy measures generally larger in patients without MetS vs those with MetS @RheumNow #ACR21 Abst#1819 https://t.co/ATxaFz9X2O https://t.co/2iJMNmfUzg

Tildrakizumab Efficacy and Safety in Patients with Psoriatic Arthritis by Metab…

Post hoc analysis of pooled data from 19 clin trials on SEC & CV risk & systemic #inflammation in PsO, PsA, AS 📌Traditional CV parameters remained stable on all SEC treated grps 📌SEC sig. ⬇hsCRP & NLR @RheumNow #ACR21 abs1835 https://t.co/iCaGFbXNXn

French study shows more than 75% of RA/SpA pregnancies resulted in a live-birth, BUT 50% of pts had at least one unfavorable pregnancy outcome! However, miscarriage prevalence lower than in reported literature. Abs 1724 #ACR21 #RheumNow @RheumNow https://t.co/64PspIKPTu https://t.co/LyfHVARAgd

More Than 50% of Women with Chronic Rheumatic Inflammatory Diseases Present an …

IVIG can passively transfer donor Ab including 'clinically significant' e.g. HBcAb @OchsnerHospMed 123 pts HBcAb+ post-IVIG 37 had HBcAb- captured pre-IVIG of those, 22 received prob unnecessary antiviral Rx Be smart: pre-IVIG, anticipate - test HBV #ACR21 ABST1528 @RheumNow

2 year study shows low rates of radiographic progression in PsA pts on guselkumab #ACR21 @RheumNow Abs#1805 https://t.co/dobg3cEXXG https://t.co/m1P24qPAhy

https://bit.ly/3ET6Pes

SERENA interim analysis on interruption of secukinumab in AS and PsA 🔹>=16 wks of Rx before interruption of >= 3 mo. 🔹75-80% of pts reinitiated w/o loading phase 🔹AS: BASDAI, PGA stable 🔹PsA: SJC, TJC returned to Rx baseline https://t.co/3G6rVW8TPv #ACR21 Abst#1361 @RheumNow

Impact of Intermediate Treatment Interruption on Secukinumab Efficacy in Patien…

Topics

All News

Telemedicine Enriched Care Model for Autoinflammatory Diseases

Do you get our email newsletter?